Company intelligence / Profile preview

RIBOPRO

Oss, North Brabant, Netherlands

Ownership: Private
Employees: ~31
Development stage: Other

Overview

RIBOPRO is not a clinical-stage developer but enables, manufactures, and licenses high-quality mRNA and LNP technologies for pioneers in RNA therapeutics, supporting partners in preclinical and clinical R&D; it has achieved rapid growth and received funding to accelerate the development and industrialization of mRNA-based drugs

Therapeutic areas: NephrologyImmunologyOphthalmologyHematologyDermatologyOncology
Modalities: mRNA-based drugsLipid nanoparticle delivery therapyRNA therapy
Industry: Drug Discovery Services

Partnerships

ArdenaImmunoPrecise Antibodies (IPA)MercurnaRadboudumcWellcome Leap Health Breakthrough NetworkImmuneSpec

Beyond the preview

Go deeper on RIBOPRO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RIBOPRO.

Explore the full profile